Forodesine

Forodesine (INN; also known as Immucillin H; trade names Mundesine and Fodosine) is a transition-state analog inhibitor of purine nucleoside phosphorylase^[1] studied for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and for treatment of B-cell acute lymphocytic leukemia (B-ALL).

Trade namesMundesine and Fodosine

Routes of
administrationoral

CAS Number

• 209799-67-7

PubChem CID

• 444499

Quick facts Clinical data, Trade names ...

Forodesine

Clinical data
Trade names	Mundesine and Fodosine
Routes of administration	oral
Identifiers
IUPAC name 7-[(2S,3S,4R,5R)-3,4-Dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-1,5-dihydropyrrolo[2,3-e]pyrimidin-4-one
CAS Number	209799-67-7
PubChem CID	444499
ChemSpider	392417
UNII	426X066ELK
KEGG	D06596
ChEMBL	ChEMBL218291
CompTox Dashboard (EPA)	DTXSID50943276
Chemical and physical data
Formula	C11H14N4O4
Molar mass	266.257 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O
InChI InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1 Key:IWKXDMQDITUYRK-KUBHLMPHBW InChI=1/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1

Close

Forodesine was originally discovered by Vern Schramm's laboratory at the Albert Einstein College of Medicine in New York and Industrial Research Limited in New Zealand.^{[citation needed]}

Forodesine is being developed by BioCryst Pharmaceuticals. As of 2008^[update], it is currently in phase II clinical trials.^{[2][needs update]}.

In 2006, BioCryst entered into a licensing agreement with Mundipharma International Holdings Limited to develop and commercialize forodesine in markets across Europe, Asia, and Australasia for use in oncology.^[3]

In April 2017, forodesine was approved in Japan for the treatment of relapsed/refractory peripheral T-cell lymphoma.^[4][5]